Rubicon Research (NSE:RUBICON) FCF Margin %: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:RUBICON Rubicon Research Ltd NSE:RUBICON
18 GF Score
Price ₹1,439.60
! 3 Warning Signs
View Full Analysis

What is Rubicon Research FCF Margin %?

Rubicon Research NSE:RUBICON +1.45% 18 FCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates NSE:RUBICON with a GF Score™ of 18/100. The stock has 3 warning signs investors should review. Among 961 Drug Manufacturers companies, Rubicon Research ranks worse than 70.34% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Rubicon Research's Free Cash Flow for the three months ended in Mar. 2026 was ₹0 Mil. Rubicon Research's Revenue for the three months ended in Mar. 2026 was ₹5,139 Mil. Therefore, Rubicon Research's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Rubicon Research's current FCF Yield % is -0.42%.

The historical rank and industry rank for Rubicon Research's FCF Margin % or its related term are showing as below:

NSE:RUBICON' s FCF Margin % Range Over the Past 10 Years
Min: -30.98   Med: -2.78   Max: 6.93
Current: -7.44

During the past 4 years, the highest FCF Margin % of Rubicon Research was 6.93%. The lowest was -30.98%. And the median was -2.78%.

NSE:RUBICON's FCF Margin % is ranked worse than
70.34% of 961 companies
in the Drug Manufacturers industry
Industry Median: 2.58 vs NSE:RUBICON: -7.44

Rubicon Research FCF Margin % Related Terms

Rubicon Research FCF Margin % Historical Data

* Premium members only.

The historical data trend for Rubicon Research's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rubicon Research FCF Margin % Chart

Rubicon Research Annual Data
Trend Mar23 Mar24 Mar25 Mar26
FCF Margin %
-30.98 -4.17 6.93 -1.38

Rubicon Research Quarterly Data
Mar23 Mar24 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial 0.00 0.00 -28.71 0.00 0.00

NSE:RUBICON vs LLY, JNJ, ABBV: FCF Margin % Comparison

For the Drug Manufacturers - General subindustry, Rubicon Research's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rubicon Research FCF Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Rubicon Research's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Rubicon Research's FCF Margin % falls into.


NSE:RUBICON
18GF Score
Rubicon Research Ltd NSE:RUBICON
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rubicon Research FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Rubicon Research's FCF Margin for the fiscal year that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (A: Mar. 2026 )/Revenue (A: Mar. 2026 )
=-241.25/17539.56
=-1.38 %

Rubicon Research's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=0/5139.15
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Rubicon Research (NSE:RUBICON) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Rubicon Research and its competitors. According to the industry distribution chart, Rubicon Research ranks #676 out of 961 companies in the Drug Manufacturers industry, placing it in the top 70.3%.
Is Rubicon Research's FCF Margin % too high?
Rubicon Research's current FCF Margin % is 0.00%. Based on the distribution chart, Rubicon Research ranks #676 out of 961 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Rubicon Research has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Rubicon Research's FCF Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Rubicon Research ranks #676 out of 961 companies for FCF Margin %. This places Rubicon Research in the lower half of its industry. The industry median FCF Margin % is 2.58. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.58, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Rubicon Research and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rubicon Research's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rubicon Research stock overvalued right now?
Rubicon Research (NSE:RUBICON) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Rubicon Research's overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Rubicon Research (NSE:RUBICON), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rubicon Research Business Description

Other Exchanges 544578:India
Address Road No. 33, MedOne House, B-75, Wagle Estate, Thane West, Thane, MH, IND, 400 604
Rubicon Research Ltd is a pharmaceutical formulations company specializing in developing, manufacturing, and marketing branded specialty and generic prescription products. Starting as a provider of contract formulation development services, the company expanded to operate an oral solids manufacturing facility in India, offering contract development and manufacturing services for regulated markets. The company's diverse product portfolio covers multiple therapeutic areas, including analgesics and pain management, CVS, CNS, hypokalemia, skeletal muscle relaxants, NRT, gastrointestinal, metabolic, and immunosuppressants. The company operates in India, the USA, and other markets, with the majority of its revenue coming from the USA.
18GF Score

Get the complete analysis for NSE:RUBICON

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,439.60
Price